BRPI1007990A2 - Compostos específicos de diaril-hidantoína e diariltioidantoína. - Google Patents
Compostos específicos de diaril-hidantoína e diariltioidantoína.Info
- Publication number
- BRPI1007990A2 BRPI1007990A2 BRPI1007990-4A BRPI1007990A BRPI1007990A2 BR PI1007990 A2 BRPI1007990 A2 BR PI1007990A2 BR PI1007990 A BRPI1007990 A BR PI1007990A BR PI1007990 A2 BRPI1007990 A2 BR PI1007990A2
- Authority
- BR
- Brazil
- Prior art keywords
- diarylthioidantoin
- compounds
- specific diaryl
- hydantoin
- diaryl hydantoin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- -1 diaryl hydantoin Chemical compound 0.000 title 1
- 229940091173 hydantoin Drugs 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/72—Two oxygen atoms, e.g. hydantoin
- C07D233/74—Two oxygen atoms, e.g. hydantoin with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to other ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US15511909P | 2009-02-24 | 2009-02-24 | |
| US15639809P | 2009-02-27 | 2009-02-27 | |
| PCT/US2010/025283 WO2010099238A1 (en) | 2009-02-24 | 2010-02-24 | Specific diarylhydantoin and diarylthiohydantoin compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1007990A2 true BRPI1007990A2 (pt) | 2015-09-01 |
Family
ID=42665887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1007990-4A BRPI1007990A2 (pt) | 2009-02-24 | 2010-02-24 | Compostos específicos de diaril-hidantoína e diariltioidantoína. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8524755B2 (pt) |
| EP (1) | EP2400847B1 (pt) |
| JP (2) | JP2012518661A (pt) |
| KR (1) | KR20110130439A (pt) |
| CN (1) | CN102421291A (pt) |
| AU (1) | AU2010218052A1 (pt) |
| BR (1) | BRPI1007990A2 (pt) |
| CA (1) | CA2753425A1 (pt) |
| ES (1) | ES2535466T3 (pt) |
| IL (1) | IL214800A0 (pt) |
| MX (1) | MX2011008858A (pt) |
| NZ (1) | NZ594741A (pt) |
| RU (1) | RU2548918C2 (pt) |
| SG (2) | SG173837A1 (pt) |
| WO (1) | WO2010099238A1 (pt) |
| ZA (2) | ZA201106200B (pt) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| WO2007127010A2 (en) * | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| EP2620432A3 (en) | 2007-10-26 | 2013-12-18 | The Regents Of the University of California | Diarylhydantoin compounds |
| US8710086B2 (en) * | 2009-04-09 | 2014-04-29 | Medivation Technologies, Inc. | Substituted di-arylhydantoin and di-arylthiohydantoin compounds and methods of use thereof |
| AU2016208310B2 (en) * | 2010-02-16 | 2017-10-05 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| AU2011218173C1 (en) | 2010-02-16 | 2015-04-16 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| AU2014271290C1 (en) * | 2010-02-16 | 2016-10-27 | Aragon Pharmaceuticals, Inc. | Androgen receptor modulators and uses thereof |
| DK2538785T3 (en) * | 2010-02-24 | 2018-05-22 | Medivation Prostate Therapeutics Llc | Methods for the synthesis of diarylthiohydantoin and diarylhydantoin compounds |
| KR20140048106A (ko) * | 2011-03-14 | 2014-04-23 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 전립선암의 치료를 위한 안드로겐 수용체 길항제와 항클러스테린 올리고뉴클레오타이드의 병용 |
| CA2843417C (en) | 2011-07-29 | 2018-08-21 | Medivation Prostate Therapeutics, Inc. | Treatment of breast cancer |
| WO2013067131A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Technologies, Inc. | Treatment methods |
| WO2013067151A1 (en) * | 2011-11-02 | 2013-05-10 | Medivation Prostate Therapeutics, Inc. | Treatment methods using diarylthiohydantoin derivatives |
| EP2664325A1 (en) * | 2012-05-16 | 2013-11-20 | PregLem S.A. | Methods for preventing or treating androgen mediated diseases |
| NZ744456A (en) | 2012-09-26 | 2019-09-27 | Aragon Pharmaceuticals Inc | Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer |
| PL2945628T3 (pl) | 2013-01-15 | 2020-09-21 | Aragon Pharmaceuticals, Inc. | Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza |
| WO2014167428A2 (en) * | 2013-04-10 | 2014-10-16 | Shilpa Medicare Limited | Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide |
| CN104803919A (zh) * | 2014-01-26 | 2015-07-29 | 上海医药工业研究院 | 用于制备恩杂鲁胺中间体的方法 |
| CN104844520B (zh) * | 2014-02-13 | 2017-09-05 | 成都伊诺达博医药科技有限公司 | 一种合成恩杂鲁胺的方法 |
| CN104844521B (zh) * | 2014-02-13 | 2017-08-15 | 成都伊诺达博医药科技有限公司 | 抗前列腺癌药物恩杂鲁胺的合成方法 |
| RU2557235C1 (ru) * | 2014-07-08 | 2015-07-20 | Александр Васильевич Иващенко | Замещенные 2-тиоксо-имидазолидин-4-оны и их спироаналоги, противораковый активный компонент, фармацевтическая композиция, лекарственный препарат, способ лечения рака простаты |
| WO2016051423A2 (en) * | 2014-10-01 | 2016-04-07 | Laurus Labs Private Limited | An improved process for the preparation of enzalutamide |
| CN107109488A (zh) | 2014-12-12 | 2017-08-29 | 麦迪韦逊前列腺治疗股份有限公司 | 预测对乳腺癌治疗剂的反应的方法和治疗乳腺癌的方法 |
| TWI613194B (zh) * | 2015-06-10 | 2018-02-01 | 台灣神隆股份有限公司 | 用於製備恩雜魯胺的新穎方法 |
| TWI726969B (zh) | 2016-01-11 | 2021-05-11 | 比利時商健生藥品公司 | 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物 |
| WO2018007624A1 (en) * | 2016-07-08 | 2018-01-11 | Actavis Group Ptc Ehf | Enzalutamide derivatives for the treatment of prostate and breast cancer |
| CN107954936B (zh) * | 2016-10-17 | 2021-03-19 | 海创药业股份有限公司 | 一种制备氘代咪唑二酮类化合物的方法 |
| CN107501237B (zh) * | 2017-08-17 | 2022-03-22 | 上海西浦医药科技有限公司 | 一种Apalutamide的合成方法 |
| US10702508B2 (en) | 2017-10-16 | 2020-07-07 | Aragon Pharmaceuticals, Inc. | Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer |
| US20210386826A1 (en) | 2018-11-05 | 2021-12-16 | Pfizer Inc. | Combination for Treating Cancer |
| AU2021325426A1 (en) | 2020-08-13 | 2023-03-09 | Astellas Pharma Inc. | Combination therapy |
| WO2022123310A1 (en) | 2020-12-11 | 2022-06-16 | Ildong Pharmaceutical Co., Ltd. | Novel compounds as androgen receptor and phosphodiesterase dual inhibitor |
| WO2022200982A1 (en) | 2021-03-24 | 2022-09-29 | Pfizer Inc. | Combination of talazoparib and an anti-androgen for the treatment of ddr gene mutated metastatic castration-sensitive prostate cancer |
| CA3230630A1 (en) | 2021-09-08 | 2023-03-16 | Curtis SWIFT | Analytical methods of assessing cytisine purity |
| CN117205216A (zh) * | 2022-05-06 | 2023-12-12 | 南京思聚生物医药有限公司 | 一种局部作用的雄激素受体拮抗剂与米诺地尔的组合物及其应用 |
| TW202425976A (zh) | 2022-12-17 | 2024-07-01 | 美商輝瑞大藥廠 | 用於治療轉移性去勢抵抗性前列腺癌之他拉唑帕尼及恩雜魯胺之組合 |
| TW202600137A (zh) | 2024-04-04 | 2026-01-01 | 美商輝瑞股份有限公司 | 於使用ｐａｒｐ抑制劑的治療作為預測性生物標記之ｔｍｐｒｓｓ２－ｅｒｇ和ｒｂｉ及使用ｐａｒｐ抑制劑之治療方法 |
| WO2026078619A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
| WO2026078615A1 (en) | 2024-10-09 | 2026-04-16 | Pfizer Inc. | Combination of talazoparib and enzalutamide in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5136332B1 (pt) | 1970-12-09 | 1976-10-07 | ||
| FR2715402B1 (fr) * | 1994-01-05 | 1996-10-04 | Roussel Uclaf | Nouvelles phénylimidazolines éventuellement substituées, leur procédé et des intermédiaires de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant. |
| GB0200283D0 (en) * | 2002-01-08 | 2002-02-20 | Smithkline Beecham Plc | Compounds |
| US7173044B2 (en) | 2004-02-19 | 2007-02-06 | Solvay Pharmaceuticals B.V. | Imidazoline derivatives having CB1-antagonistic activity |
| US20060030871A1 (en) | 2004-08-05 | 2006-02-09 | Matthew Hain | Vascular tunneler |
| EP1784852A2 (en) * | 2004-08-26 | 2007-05-16 | Philips Intellectual Property & Standards GmbH | Lamp with reflective coating |
| US8470829B2 (en) * | 2004-09-09 | 2013-06-25 | Chugai Seiyaku Kabushiki Kaisha | Imidazolidine derivative and use thereof |
| NZ564223A (en) * | 2005-05-13 | 2011-03-31 | Univ California | Diarylhydantoin compounds for treating hormone refractory prostate cancer |
| US7709517B2 (en) | 2005-05-13 | 2010-05-04 | The Regents Of The University Of California | Diarylhydantoin compounds |
| ATE387259T1 (de) * | 2005-05-13 | 2008-03-15 | Protectron Nanocomposites Pte | Verbessertes kolloidales gel für schützendes textiles flächengebilde, verbessertes schützendes textiles flächengebilde und herstellungsverfahren dafür |
| WO2007127010A2 (en) | 2006-03-29 | 2007-11-08 | The Regents Of The University Of California | Diarylthiohydantoin compounds |
| EP2620432A3 (en) | 2007-10-26 | 2013-12-18 | The Regents Of the University of California | Diarylhydantoin compounds |
-
2010
- 2010-02-24 SG SG2011061066A patent/SG173837A1/en unknown
- 2010-02-24 MX MX2011008858A patent/MX2011008858A/es active IP Right Grant
- 2010-02-24 ES ES10746795.3T patent/ES2535466T3/es active Active
- 2010-02-24 BR BRPI1007990-4A patent/BRPI1007990A2/pt not_active IP Right Cessation
- 2010-02-24 CA CA2753425A patent/CA2753425A1/en not_active Abandoned
- 2010-02-24 NZ NZ594741A patent/NZ594741A/en not_active IP Right Cessation
- 2010-02-24 AU AU2010218052A patent/AU2010218052A1/en not_active Abandoned
- 2010-02-24 CN CN2010800179543A patent/CN102421291A/zh active Pending
- 2010-02-24 US US13/202,970 patent/US8524755B2/en active Active
- 2010-02-24 JP JP2011551318A patent/JP2012518661A/ja not_active Ceased
- 2010-02-24 RU RU2011139107/04A patent/RU2548918C2/ru not_active IP Right Cessation
- 2010-02-24 KR KR1020117022048A patent/KR20110130439A/ko not_active Ceased
- 2010-02-24 SG SG10201402628VA patent/SG10201402628VA/en unknown
- 2010-02-24 EP EP10746795.3A patent/EP2400847B1/en not_active Revoked
- 2010-02-24 WO PCT/US2010/025283 patent/WO2010099238A1/en not_active Ceased
-
2011
- 2011-08-23 ZA ZA2011/06200A patent/ZA201106200B/en unknown
- 2011-08-23 IL IL214800A patent/IL214800A0/en unknown
-
2013
- 2013-05-14 ZA ZA2013/03499A patent/ZA201303499B/en unknown
- 2013-06-24 US US13/925,507 patent/US9023879B2/en active Active
-
2014
- 2014-11-07 JP JP2014227148A patent/JP2015028085A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110130439A (ko) | 2011-12-05 |
| ES2535466T3 (es) | 2015-05-11 |
| EP2400847B1 (en) | 2014-12-17 |
| ZA201106200B (en) | 2013-07-31 |
| EP2400847A4 (en) | 2012-08-08 |
| JP2015028085A (ja) | 2015-02-12 |
| JP2012518661A (ja) | 2012-08-16 |
| CN102421291A (zh) | 2012-04-18 |
| IL214800A0 (en) | 2011-11-30 |
| RU2011139107A (ru) | 2013-04-10 |
| SG10201402628VA (en) | 2014-10-30 |
| AU2010218052A1 (en) | 2011-09-08 |
| CA2753425A1 (en) | 2010-09-02 |
| WO2010099238A1 (en) | 2010-09-02 |
| ZA201303499B (en) | 2015-03-25 |
| US8524755B2 (en) | 2013-09-03 |
| NZ594741A (en) | 2014-03-28 |
| US20130331421A1 (en) | 2013-12-12 |
| MX2011008858A (es) | 2012-01-27 |
| EP2400847A1 (en) | 2012-01-04 |
| RU2548918C2 (ru) | 2015-04-20 |
| US20120035231A1 (en) | 2012-02-09 |
| SG173837A1 (en) | 2011-09-29 |
| US9023879B2 (en) | 2015-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1007990A2 (pt) | Compostos específicos de diaril-hidantoína e diariltioidantoína. | |
| NO2021006I1 (no) | Quofenix, delafloksacin | |
| BRPI0815717A2 (pt) | Compostos de imidazopirazina. | |
| BRPI1007310A2 (pt) | Compostos inseticidas. | |
| BRPI0921327A2 (pt) | Combinação de herbicida-protetor | |
| BRPI0807473A2 (pt) | Recipiente, javre e conjunto de recipiente e javre | |
| BRPI0821868A2 (pt) | Grânulo | |
| FR2943512B1 (fr) | Applicateur metallique. | |
| EP2307845A4 (en) | LOCK HOLSTER | |
| BRPI1009415A2 (pt) | escova de dentes. | |
| BRPI1016117A2 (pt) | derivados de isoxazol-isoxazol e isoxasol-isotiazol. | |
| BRPI0907108A2 (pt) | escova de dentes. | |
| BRPI1011460A2 (pt) | Composição desinfetante. | |
| SE0801651L (sv) | Granuleringskvarn | |
| EP2259958A4 (en) | LINKAGE | |
| IT1396487B1 (it) | Convogliatore. | |
| BRPI0912716A2 (pt) | composto. | |
| BRPI0922728A2 (pt) | combinação de herbicida-antídoto | |
| IT1391534B1 (it) | Barriera. | |
| BRPI0920116A2 (pt) | membro de vedação | |
| EP2300594A4 (en) | ELECTROBIOCHEMICAL REACTOR | |
| BRPI1014244A2 (pt) | composto de polipropileno-talco estabilizado. | |
| IT1396642B1 (it) | Statore. | |
| DE112009001669A5 (de) | Sektionaltor | |
| EP2256754A4 (en) | REACTOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |